AstraZeneca Starts Artificial Intelligence Collaboration to Accelerate Drug Discovery

AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
Source: eHealth News EU - Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news